Rapid Micro Biosystems, Inc. reported a total revenue of $33.6 million for the fiscal year ending December 31, 2025, marking a 19.7% increase from $28.1 million in 2024. The company incurred a net loss of $47.1 million, slightly higher than the $46.9 million loss reported in the previous year. As of December 31, 2025, Rapid Micro had an accumulated deficit of $522.4 million. The increase in revenue was primarily driven by a rise in product sales, particularly from the Growth Direct systems and consumables, which saw a 25.1% increase in product revenue to $23.4 million. Service revenue also grew by 9.0%, reaching $10.2 million, attributed to higher validation and installation services.
The company experienced significant operational changes, including the placement of 28 new Growth Direct systems in 2025, bringing the total to 190 systems across 49 customers globally. This expansion included 75% of the top 20 largest pharmaceutical companies, indicating a strong market presence. Additionally, Rapid Micro has made strides in its recurring revenue model, with consumables and service contracts contributing to 53.1% of total revenue. The company has also entered into a Distribution and Collaboration Agreement with Millipore S.A.S., allowing for global co-exclusive sales of its products, which is expected to enhance market penetration and revenue growth.
Operationally, Rapid Micro has focused on improving its gross margins, which turned positive for the first time in its history, increasing from (0.4)% in 2024 to 3.1% in 2025. The company aims to maintain this upward trend by reducing costs and increasing manufacturing efficiency. As of December 31, 2025, Rapid Micro employed 171 full-time staff, with a focus on expanding its sales and marketing capabilities to drive further adoption of its Growth Direct platform.
Looking ahead, Rapid Micro anticipates continued growth driven by the increasing adoption of its automated microbial quality control solutions in the pharmaceutical industry, particularly in biologics and cell and gene therapies. The company aims to leverage its first-mover advantage in the automated MQC market and expand its product offerings. However, it acknowledges the potential for ongoing losses and the need for additional capital to support its growth strategy. The company has indicated that it expects to fund its operations for at least the next 12 months with its current cash and investments, totaling $38.6 million as of December 31, 2025.
About RAPID MICRO BIOSYSTEMS, INC.
Rapid Micro Biosystems specializes in automating microbial quality control testing for pharmaceutical manufacturing. Its flagship Growth Direct platform offers rapid, accurate, and secure detection of microbial contamination, supporting biologics, vaccines, and sterile injectables. The company's solutions enhance operational efficiency, data integrity, and regulatory compliance, serving global pharmaceutical and biotech companies. Its business model emphasizes recurring revenue from system sales, consumables, and support services.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.